U.S. payers are warming up to covering digital therapeutics

Multichannel Payer Marketing 2020

70% of formulary decision-makers cover or are interested in covering digital therapeutics.

Increasingly sophisticated and often clinically-validated digital health tools and therapeutics (DTx) are coming to market. However, in the fragmented U.S. market, a big potential barrier remains: the question of who will pay for them. Study data suggest payers are warming to this emerging field of technologies.

Clarivate surveyed 157 U.S. P&T committee members and found that nearly half agree that “Digital therapeutics are the future of healthcare.” Among these healthcare executives, who make formulary decisions within hospitals, IDNs, MCOs and PBMs, 25% said their organization currently provides coverage for DTx, and another 45% expressed interest in providing coverage.